Browse > Article
http://dx.doi.org/10.3904/kjim.2018.162

Neuropathic cancer pain: prevalence, pathophysiology, and management  

Yoon, So Young (Division of Oncology, Department of Internal Medicine, Konkuk University School of Medicine)
Oh, Jeeyoung (Department of Neurology, Konkuk University School of Medicine)
Publication Information
The Korean journal of internal medicine / v.33, no.6, 2018 , pp. 1058-1069 More about this Journal
Abstract
Neuropathic cancer pain (NCP) is caused by nerve damage attributable to the cancer per se, and/or treatments including chemotherapy, radiotherapy, and surgery; the prevalence is reported to be as high as 40%. The etiologies of NCP include direct nerve invasion or nerve compression by the cancer, neural toxicity, chemotherapy, and radiotherapy. NCP is subdivided into plexopathy, radiculopathy, and peripheral neuropathies, among several other categories. The clinical characteristics of NCP differ from those of nociceptive pain in terms of both the hypersensitivity symptoms (burning, tingling, and an electrical sensation) and the hyposensitivity symptoms (numbness and muscle weakness). Recovery requires several months to years, even after recovery from injury. Management is complex; NCP does not usually respond to opioids, although treatments may feature both opioids and adjuvant drugs including antidepressants, anticonvulsants, and anti-arrhythmic agents, all of which improve the quality-of-life. This review addresses the pathophysiology, clinical characteristics and management of NCP, and factors rendering pain control difficult.
Keywords
Neuralgia; Neoplasms; Chemotherapy drugs;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Backonja MM, Attal N, Baron R, et al. Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. Pain 2013;154:1807-1819.   DOI
2 Terkelsen AJ, Karlsson P, Lauria G, Freeman R, Finnerup NB, Jensen TS. The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes. Lancet Neurol 2017;16:934-944.   DOI
3 Chan AC, Wilder-Smith EP. Small fiber neuropathy: getting bigger! Muscle Nerve 2016;53:671-682.   DOI
4 Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32:1941-1967.   DOI
5 Freynhagen R, Bennett MI. Diagnosis and management of neuropathic pain. BMJ 2009;339:b3002.   DOI
6 Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev 2015;(7):CD008242.
7 Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309:1359-1367.   DOI
8 Henry NL, Unger JM, Schott AF, et al. Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202. J Clin Oncol 2018;36:326-332.
9 Durand JP, Deplanque G, Montheil V, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 2012;23:200-205.   DOI
10 National Comprehensive Cancer Network. NCCN guidelines version 1 [Internet]. Fort Washington (PA): NCCN, c2018 [cited 2018 May 16]. Available from: www.nccn.org.
11 Mishra S, Bhatnagar S, Goyal GN, Rana SP, Upadhya SP. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care 2012;29:177-182.   DOI
12 de Andrade DC, Jacobsen Teixeira M, Galhardoni R, et al. Pregabalin for the prevention of oxaliplatin-induced painful neuropathy: a randomized, double-blind trial. Oncologist 2017;22:1154-e105.   DOI
13 Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162-173.   DOI
14 Knezevic NN, Tverdohleb T, Nikibin F, Knezevic I, Candido KD. Management of chronic neuropathic pain with single and compounded topical analgesics. Pain Manag 2017;7:537-558.   DOI
15 Nicholson B. Differential diagnosis: nociceptive and neuropathic pain. Am J Manag Care 2006;12(9 Suppl):S256-S262.
16 van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437-1449.   DOI
17 Oldenmenger WH, Sillevis Smitt PA, van Dooren S, Stoter G, van der Rijt CC. A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal. Eur J Cancer 2009;45:1370-1380.   DOI
18 Bennett MI, Rayment C, Hjermstad M, Aass N, Caraceni A, Kaasa S. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain 2012;153:359-365.   DOI
19 Lema MJ, Foley KM, Hausheer FH. Types and epidemiology of cancer-related neuropathic pain: the intersection of cancer pain and neuropathic pain. Oncologist 2010;15 Suppl 2:3-8.
20 Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-1635.   DOI
21 Oosterling A, te Boveldt N, Verhagen C, et al. Neuropathic pain components in patients with cancer: prevalence, treatment, and interference with daily activities. Pain Pract 2016;16:413-421.   DOI
22 Oh SY, Shin SW, Koh SJ, et al. Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients. Support Care Cancer 2017;25:3759-3767.   DOI
23 Rayment C, Hjermstad MJ, Aass N, et al. Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study. Palliat Med 2013;27:714-721.   DOI
24 Urch CE, Dickenson AH. Neuropathic pain in cancer. Eur J Cancer 2008;44:1091-1096.   DOI
25 Garzon-Rodriguez C, Lyras L, Gayoso LO, et al. Cancer-related neuropathic pain in out-patient oncology clinics: a European survey. BMC Palliat Care 2013;12:41.   DOI
26 Boland EG, Mulvey MR, Bennett MI. Classification of neuropathic pain in cancer patients. Curr Opin Support Palliat Care 2015;9:112-115.   DOI
27 Fallon MT. Neuropathic pain in cancer. Br J Anaesth 2013;111:105-111.   DOI
28 Vecht CJ. Nociceptive nerve pain and neuropathic pain. Pain 1989;39:243-246.   DOI
29 Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014;155:2461-2470.   DOI
30 Sisignano M, Baron R, Scholich K, Geisslinger G. Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain. Nat Rev Neurol 2014;10:694-707.   DOI
31 Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 2013;63:419-437.   DOI
32 Fernandes R, Mazzarello S, Majeed H, et al. Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy: a systematic review. Support Care Cancer 2016;24:1583-1594.   DOI
33 Loprinzi CL, Reeves BN, Dakhil SR, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 2011;29:1472-1478.   DOI
34 Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain 2016;157:560-568.   DOI
35 Reeves BN, Dakhil SR, Sloan JA, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer 2012;118:5171-5178.   DOI
36 Griffith KA, Zhu S, Johantgen M, et al. Oxaliplatin-induced peripheral neuropathy and identification of unique severity groups in colorectal cancer. J Pain Symptom Manage 2017;54:701-706.   DOI
37 Pachman DR, Qin R, Seisler DK, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III Trial N08CB (Alliance). J Clin Oncol 2015;33:3416-3422.   DOI
38 Loprinzi CL, Maddocks-Christianson K, Wolf SL, et al. The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J 2007;13:399-403.   DOI
39 Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 2012;14 Suppl 4:iv45-iv54.
40 Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 2015;75:659-670.   DOI
41 Finnerup NB, Haroutounian S, Kamerman P, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain 2016;157:1599-1606.   DOI
42 Bennett M. The LANSS Pain Scale: the leeds assessment of neuropathic symptoms and signs. Pain 2001;92:147-157.   DOI
43 Abdallah FW, Morgan PJ, Cil T, Escallon JM, Semple JL, Chan VW. Comparing the DN4 tool with the IASP grading system for chronic neuropathic pain screening after breast tumor resection with and without paravertebral blocks: a prospective 6-month validation study. Pain 2015;156:740-749.   DOI
44 Park C, Lee YW, Yoon DM, Kim DW, Nam DJ, Kim DH. Cross-cultural adaptation and linguistic validation of the Korean version of the Leeds assessment of neuropathic symptoms and signs pain scale. J Korean Med Sci 2015;30:1334-1339.   DOI
45 Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:29-36.   DOI
46 Kim HJ, Park JH, Bouhassira D, et al. Validation of the Korean version of the DN4 diagnostic questionnaire for neuropathic pain in patients with lumbar or lumbar-radicular pain. Yonsei Med J 2016;57:449-454.   DOI
47 Freynhagen R, Baron R, Gockel U, Tolle TR. PainDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911-1920.   DOI
48 Cruccu G, Sommer C, Anand P, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol 2010;17:1010-1018.   DOI
49 Rog DJ, Nurmikko TJ, Friede T, Young CA. Validation and reliability of the Neuropathic Pain Scale (NPS) in multiple sclerosis. Clin J Pain 2007;23:473-481.   DOI
50 Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the neuropathic pain symptom inventory. Pain 2004;108:248-257.   DOI
51 Valeriani M, Pazzaglia C, Cruccu G, Truini A. Clinical usefulness of laser evoked potentials. Neurophysiol Clin 2012;42:345-353.   DOI